Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...

Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but ...

The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous ...

Direct costs associated with IBD include ambulatory visits to gastroenterologists, emergency department visits, admissions ...

Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by ...

On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, ...

By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster ...

Number 4: Regulatory experts and representatives from some of the top biosimilar manufacturers emphasized the importance of ...

In October, the GRx+Biosims conference included discussions on data transparency, artificial intelligence, and collaboration ...

Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses how integrated delivery networks (IDNs) can help drive biosimilar adoption. Sophia Humphreys, ...